Mutations and MRD: clinical implications of clonal ontogeny

2.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

3.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

4.

Short

NJ

,

Zhou

S

,

Fu

C

, et al.

Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis

.

JAMA Oncol

.

2020

;

6

(

12

):

1890

-

1899

.

5.

Heuser

M

,

Freeman

SD

,

Ossenkoppele

GJ

, et al.

2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

.

Blood

.

2021

;

138

(

26

):

2753

-

2767

.

6.

Chen

J

,

Gale

RP

,

Hu

Y

, et al.

Measurable residual disease (MRD) testing in haematological and solid tumors

.

Leukemia

.

2024

;

38

:

1202

-

1212

.

7.

Wienecke

CP

,

Heida

B

,

Venturini

L

, et al.

Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation

.

Blood

.

2024

;

144

(

3

):

296

-

307

.

8.

Paras

G

,

Morsink

LM

,

Othus

M

, et al.

Conditioning intensity and peri-transplant flow cytometric MRD dynamics in adult AML

.

Blood

.

2022

;

139

(

11

):

1694

-

1706

.

9.

Hourigan

CS

,

Dillon

LW

,

Gui

G

, et al.

Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease

.

J Clin Oncol

.

2020

;

38

(

12

):

1273

-

1283

.

10.

Dillon

LW

,

Gui

G

,

Page

KM

, et al.

DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant

.

JAMA

.

2023

;

329

(

9

):

745

-

755

.

11.

Rodríguez-Arbolí

E

,

Othus

M

,

Orvain

C

, et al.

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

.

Haematologica

.

2023

;

108

(

1

):

273

-

277

.

12.

Dillon

LW

,

Gui

F

,

Ravindra

N

, et al.

Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia

.

JAMA Oncol

.

2024

;

10

(

8

):

1104

-

1110

.

13.

Tsai

X-C

,

Sun

K-J

,

Lo

M-Y

, et al.

Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML

.

Blood Cancer J

.

2023

;

13

(

1

):

4

.

14.

Lindsley

RC

,

Mar

BG

,

Mazzola

E

, et al.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

.

Blood

.

2015

;

125

(

9

):

1367

-

1376

.

15.

Godley

LA

.

Germline mutations in MDS/AML predisposition disorders

.

Curr Opin Hematol

.

2021

;

28

(

2

):

86

-

93

.

16.

Stengel

A

,

Baer

C

,

Walter

W

, et al.

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies

.

Blood Adv

.

2021

;

5

(

21

):

4426

-

4434

.

17.

Hirsch

P

,

Tang

R

,

Abermil

N

, et al.

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia

.

Haematologica

.

2017

;

102

(

7

):

1227

-

1237

.

18.

Dillon

LW

,

Higgins

J

,

Nasif

H

, et al.

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

.

Haematologica

.

2024

;

109

(

2

):

401

-

410

.

19.

Jongen-Lavrencic

M

,

Grob

T

,

Hanekamp

D

, et al.

Molecular minimal residual disease in acute myeloid leukemia

.

N Engl J Med

.

2018

;

378

(

13

):

1189

-

1199

.

20.

Murphy

T

,

Zou

J

,

Arruda

A

, et al.

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia

.

Haematologica

.

2024

;

109

(

2

):

671

-

675

.

21.

Klco

JM

,

Miller

CA

,

Griffith

M

, et al.

Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia

.

JAMA

.

2015

;

314

(

8

):

811

-

822

.

22.

Slade

MJ

,

Ghasemi

R

,

O'Laughlin

M

, et al.

Persistent molecular disease in adult patients with AML evaluated with whole-exome and targeted error-corrected DNA sequencing

.

JCO Precis Oncol

.

2023

;

7

:

e2200559

.

23.

Othus

M

,

Wood

BL

,

Stirewalt

DL

, et al.

Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

.

Leukemia

.

2016

;

30

(

10

):

2080

-

2083

.

24.

Romer-Seibert

JS

,

Meyer

SE

.

Genetic heterogeneity and clonal evolution in acute myeloid leukemia

.

Curr Opin Hematol

.

2021

;

28

(

1

):

64

-

70

.

25.

Duchmann

M

,

Laplane

L

,

Itzykson

R.

Clonal architecture and evolutionary dynamics in acute myeloid leukemias

.

Cancers (Basel)

.

2021

;

13

(

19

):

4887

.

26.

Onecha

E

,

Rapado

I

,

Luz Morales

M

, et al.

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse

.

Haematologica

.

2021

;

106

(

9

):

2325

-

2333

.

27.

Vosberg

S

,

Greif

PA

.

Clonal evolution of acute myeloid leukemia from diagnosis to relapse

.

Genes Chromosomes Cancer

.

2019

;

58

(

12

):

839

-

849

.

28.

Nuno

K

,

Azizi

A

,

Koehnke

T

, et al.

Convergent epigenetic evolution drives relapse in acute myeloid leukemia

.

Elife

.

2024

;

13

:

e93019

.

29.

Paguirigan

AL

,

Smith

J

,

Meshinchi

S

,

Carroll

M

,

Maley

C

,

Radich

JP

.

Single- cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia

.

Sci Transl Med

.

2015

;

7

(

281

):

281re2

.

30.

Morita

K

,

Wang

F

,

Jahn

K

, et al.

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

.

Nat Commun

.

2020

;

11

(

1

):

5327

.

31.

Miles

LA

,

Bowman

RL

,

Merlinsky

TR

, et al.

Single-cell mutation analysis of clonal evolution in myeloid malignancies

.

Nature

.

2020

;

587

(

7834

):

477

-

482

.

32.

Robinson

TM

,

Bowman

RL

,

Persaud

S

, et al.

Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

.

Sci Adv

.

2023

;

9

(

38

):

eadg0488

.

33.

Dillon

LW

,

Ghannam

J

,

Nosiri

C

, et al.

Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis

.

Blood Cancer Discov

.

2021

;

2

(

4

):

319

-

325

.